Over the years, a key element of our development program has been to publish and present our findings at major medical meetings. Dennis Kim, to provide an overview of our progress in RESPONSE, as well as across the entire PBC development program. Today, I'll ask our chief medical officer, Dr. Our current experience includes patients who have been on treatment for between three months and up to three years.
We have explored a broad range of doses between two and 200 milligrams and have studied a wide spectrum of patients, including non-cirrhotic and compensated cirrhotic with and without portal hypertension. We believe our development program for seladelpar is one of the most robust ever conducted in patients with PBC with over 600 participants, including over 325 currently receiving treatment in our ongoing studies.
CBAY TRANSCRIPTIONS REGISTRATION
Last week, we announced the completion of enrollment in RESPONSE, our global phase 3 registration study evaluating seladelpar in PBC patients who have had an inadequate response to or are intolerant to first-line treatment ursodeoxycholic acid.Īs a result of the tireless efforts of our team here at CymaBay, the commitment of our patients and their family members, the expertise of our investigators and their staff and the support of our investors, we have been able to bring seladelpar a step closer to our goal of improving the lives of patients with PBC. I'm excited to start our call today, highlighting the achievement of a significant milestone in the development of seladelpar for patients with the rare autoimmune liver disease, primary biliary cholangitis, or PBC. Good afternoon, and thank you for joining us today. Actual outcomes and results are subject to risks and uncertainties and could differ materially from those forecast due to the impact of many factors. Although the company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions. Before we begin, I'd like to remind everyone that statements made during this conference call, including the Q&A session relating to CymaBay's expected future performance, business prospects, events or plans, including clinical plans, regulatory approvals, funding and repayment schedules, anticipated time lines and data release date, cash runway and planning for commercialization are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Joining me on the call today are Sujal Shah, chief executive officer Chuck McWherter, chief scientific officer Dennis Kim, chief medical officer Lewis Stuart, chief commercial officer and Dan Menold, VP, finance.įollowing our prepared remarks, we will open the call for Q&A.
You can access that release on our website under the Investors tab. I hope that you've had a chance to review the press release we issued announcing our second quarter 2022 financial results and business updates. Thank you, operator, and good afternoon, everyone.
0 kommentar(er)
